Apeiron Nominated for the Most Important European Biotechnology Award
Vienna-based biotech company Apeiron Biologics AG has been
nominated as one of three finalists for the European Biotechnica
Award. The Biotechnica Award, which is presented by Deutsche
Messe AG as part of the sector's leading trade fair, is regarded as
Europe's most prestigious biotech award. Apeiron is the only
unlisted finalist. The company first caught the attention of industry
insiders in January 2010 when it signed a licensing agreement with
GlaxoSmithKline (GSK) valued at EUR 236 million for the rights to
Apeiron’s lead product APN01.
(firmenpresse) - Today, the Vienna-based biotech company APEIRON Biologics
AG confirmed the nomination as a finalist for the European
Biotechnica Award, together with two other competitors. The
award distinguishes companies operating in the field of
biotechnology and life sciences which have excelled in the
sector through innovative products, services and business ideas.
The award will be presented by Deutsche Messe AG as kick-off
to the industry's leading trade fair, Biotechnica, which is to be
held this year from October 5th-7th in Hannover.
An Eventful Year for Apeiron
Only six months ago, a licensing agreement with a total deal
volume of approx. EUR 236 million was signed for the lead
product APN01, a drug candidate for treatment of Acute
Respiratory Distress Syndrome (ARDS). This agreement with
GSK was the starting point for the expansion of the company's
development pipeline, focussing on the field of biological and
immunological cancer therapies. As Dr. Hans Loibner, CEO of
Apeiron states: "The licensing deal with GSK has contributed
substantially to strengthening Apeiron's financial base. As such,
we are now able to diversify our pipeline, both through in-house
developed projects, as well as by licensing-in more established
clinical projects. The nomination by the jury of the European
Biotechnica Award has confirmed to us and to potential licensing
partners that the path Apeiron has taken is the right one. It goes
without saying that we are very pleased about this nomination!"
Taking the Road Less Travelled
Together with Apeiron, Addex Pharmaceuticals from Switzerland
and Galapagos Genomics from Belgium qualified for the final
round this year. In contrast to Apeiron, both other companies are
listed on stock exchanges. This is something that makes
Apeiron's nomination particularly interesting to investors. In
connection with the GSK deal, Apeiron stunned industry experts
when the company disclosed that professional development of
the then licensed-out lead product had been carried out from
basic research until completion of the first clinical phase without
venture capital and involving a total sum of no more than around
EUR 6.5 million. Commenting on this success, Dr. Loibner stated
that "Apeiron is in the fortunate position of being able to draw on
a wealth of expertise. On the one hand, the company has the
experience of being able to identify promising and innovative
projects. On the other hand, it is able to implement its projects in
a targeted and focused way – from pre-clinical to advanced
clinical testing stages – in accordance with the highest industry
standards, and is capable of designing clinical development to
be as efficient as possible. Of course, all this maximises the
value that is generated within the company – as the GSK deal
has impressively shown."
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
About Apeiron (August 2010)
Apeiron Biologics AG is a privately financed Biotech company
based in Vienna. In February 2010, the then lead product APN01
(recombinant human Angiotensin Converting Enzyme 2, rhACE2),
an enzyme-based bio-therapeutic for treatment of Acute
Respiratory Distress Syndrome (ARDS) and a series of other
diseases, was licensed out to GSK in a milestone-based
agreement for approx. EUR 236 million. Currently, building on an
existing set of innovative in-house projects, Apeiron is expanding
its portfolio with clinical projects up to Phase II with a focus on
biologic / immunologic therapy of cancer. Apeiron employs 15
members of staff at its main site, the Campus Vienna Biocenter.
Contact Apeiron:
Dr. Hans Loibner, CEO
Campus-Vienna-Biocenter 5
1030 Wien
Austria
T +43 / 1 / 865 6577
E apeiron(at)apeiron-biologics.com
W www.apeiron-biologics.com
Copy Editing & Distribution:
PR&D - Public Relations for Research & Education
Campus-Vienna-Biocenter 2
1030 Wien
Austria
T +43 / 1 / 505 70 44
E contact(at)prd.at
W www.prd.at
Datum: 19.08.2010 - 11:28 Uhr
Sprache: Deutsch
News-ID 1018552
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Phone:
Kategorie:
Pharmaceuticals & Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 335 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Apeiron Nominated for the Most Important European Biotechnology Award
"
steht unter der journalistisch-redaktionellen Verantwortung von
PR&D - Public Relations for Research & Education (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
